Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Clinical trial NCT01403285 · TERMINATED
Trial details
- NCT number
- NCT01403285
- Sponsor
- Immatics Biotechnologies GmbH
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-08-01
- Primary completion
- 2014-04-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.